Our Science

Our Boltbody™ platform consists of systemically delivered Immune-Stimulating Antibody Conjugates (ISAC). We conjugate tumor-targeting antibodies to powerful immune stimulants such as TLR agonists, proven to convert cold tumors into immunologically hot tumors, and have demonstrated that Boltbody™ ISACs eliminate tumors in preclinical models following systemic administration.

Addressing Cancer Systemically

1

IMMUNE TARGETED THERAPY

Checkpoint inhibitor innovations, such as anti-PD-(L)-1, take the brakes off patient’s T cells so they can kill tumor cells. Checkpoint therapy has proven to extend survival, but is not effective for many because the patient’s tumor-specific immune system is “cold”. To address this issue clinical trials demonstrate that therapies targeting Toll-Like Receptors (TLRs) in the tumor can re-activate the immune system, often enabling tumor shrinkage in combination with Checkpoint therapy. However, TLR therapy requires intratumoral injection because systemic delivery can create immune system activation safety issues.

2

TUMOR TARGETED THERAPY

Systemic administration of tumor-targeting agents enables cancer treatments to reach tumors inaccessible by direct intratumoral injection and to reach metastatic disease. Specifically, monoclonal antibodies (mAb) allow a systemically administered therapy to be targeted to the site of disease where tumors express the mAb antigen target. mAb therapies are augmented by Antibody Drug Conjugates (ADC) where chemotherapeutic drugs are linked to mAbs. mAbs allow systemic administration of ADCs with highly-toxic payloads that selectively eliminate target tumor cells while sparing healthy tissue.

3

TUMOR & IMMUNE TARGETED THERAPY

Immune Stimulating Antibody Conjugates (ISAC) systemically deliver powerful immune-stimulating payloads, such as TLR agonist, to the targeted tumor with  mAbs. This novel therapeutic has demonstrated tumor eradication as a monotherapy in preclinical models and activation of the innate immune system to generate an adaptive immune response which leads to durable T cell-mediated tumor clearance and surveillance. Bolt’s considerable experience in dendritic cell biology and insight into the human immune system led to the discovery of the Boltbody™️ ISAC.

The Boltbody™ platform reinvigorates the immune system and builds on our understanding of how dendritic and other myeloid cells generate effective anti-tumor immunity. Boltbody™ ISACs are a unique class of immuno-oncology therapies whose capabilities hold the promise of generating systemic immunological memory with durable clinical benefit.

Dr. Edgar G. Engleman, M.D., Director, Immunology & Immunotherapy of Cancer Programs, Stanford Cancer Institute. Bolt Founder and Board Member.

THE PROMISE OF IMMUNOLOGICAL MEMORY

Boltbody™ ISACs selectively target tumors for destruction by the immune system. Tumor-associated myeloid cells engulf ISAC-bound tumors, become armed with tumor neoantigens, and migrate to the lymph nodes where they mediate the activation and expansion of tumor-reactive T cells. In preclinical tumor models, ISAC therapy leads to regression of established tumors and generation of immunological memory, which guards against the recurrence of tumors that express tumor neoantigens even if they no longer express the ISAC target antigen.

Investors

News & Publications

Our Team

Management

Board

Careers

Bolt Biotherapeutics is a vibrant biotechnology company actively developing its novel Boltbody™ platform, a cancer immunotherapy that consists of Immune-Stimulating Antibody Conjugates (ISAC). Located in the San Francisco Bay Area, Bolt is led by a team with extensive oncology drug development experience and is seeking bright, self-motivated individuals who share their passion for bringing novel and curative biotherapies to patients in need. If you enjoy a collaborative and fun environment with all the benefits and challenges that come with working at a cutting-edge biotherapeutics company, please contact us at 650.665.9295 or jobs@boltbio.com for more information.

Here are some positions we’re hiring:

Senior Director, Human Resources
Office Manager / Executive Assistant
Senior Preclinical Research Associate / Scientist I
Senior Project Manager / Associate Director of Project Management

Contact Us

4 + 0 = ?

Boltbody™ Immune-Stimulating Antibody Conjugates

Bolt Biotherapeutics, Inc.
640 Galveston Drive
Redwood City, CA 94063